1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Systemic Therapy inMen With MetastaticCastration-ResistantProstate Cancer:American Society ofClinical Oncology andCancer Care OntarioClinical Practice… Ethan BaschD.A. LoblawThomas K. Oliver2014 год

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
review

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Purpose To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC). Methods The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the literature. Results When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ( 223 Ra; for men with predominantly bone metastases). Improved survival and QOL with moderate toxicity risk are associated with docetaxel/prednisone. For asymptomatic/minimally symptomatic men, improved survival with unclear QOL impact and low toxicity are associated with sipuleucel-T. For men who previously received docetaxel, improved survival, unclear QOL impact, and moderate to high toxicity risk are associated with cabazitaxel/prednisone. Modest QOL benefit (without survival benefit) and high toxicity risk are associated with mitoxantrone/prednisone after docetaxel. No benefit and excess toxicity are observed with bevacizumab, estramustine, and sunitinib. Recommendations Continue androgen deprivation (pharmaceutical or surgical) indefinitely. Abiraterone acetate/prednisone, enzalutamide, or 223 Ra should be offered; docetaxel/prednisone should also be offered, accompanied by discussion of toxicity risk. Sipuleucel-T may be offered to asymptomatic/minimally symptomatic men. For men who have experienced progression with docetaxel, cabazitaxel may be offered, accompanied by discussion of toxicity risk. Mitoxantrone may be offered, accompanied by discussion of limited clinical benefit and toxicity risk. Ketoconazole or antiandrogens (eg, bicalutamide, flutamide, nilutamide) may be offered, accompanied by discussion of limited known clinical benefit. Bevacizumab, estramustine, and sunitinib should not be offered. There is insufficient evidence to evaluate optimal sequences or combinations of therapies. Palliative care should be offered to all patients.
Год издания: 2014
Авторы: Ethan Basch, D.A. Loblaw, Thomas K. Oliver, Michael A. Carducci, Ronald C. Chen, James N. Frame, Kristina Garrels, Sébastien J. Hotte, Michael W. Kattan, Derek Raghavan, Fred Saad, Mary-Ellen Taplin, Cindy Walker‐Dilks, J. Koudy Williams, Eric Winquist, Charles L. Bennett, Ted Wootton, R. Bryan Rumble, Stacie B. Dusetzina, Katherine S. Virgo
Издательство: Lippincott Williams & Wilkins
Источник: Journal of Clinical Oncology
Ключевые слова: Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment
Другие ссылки: Journal of Clinical Oncology (HTML)
Europe PMC (PubMed Central) (PDF)
Europe PMC (PubMed Central) (HTML)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (PDF)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (HTML)
PubMed Central (HTML)
PubMed (HTML)